High-dose Furmonertinib in the Treatment in Patients With Advanced, Metastatic NSCLC With Progressed After First- or Second-line Treatment With Osimertinib

PHASE2RecruitingINTERVENTIONAL
Enrollment

84

Participants

Timeline

Start Date

May 1, 2024

Primary Completion Date

June 30, 2025

Study Completion Date

September 30, 2026

Conditions
Non-Small Cell Lung Cancer
Interventions
DRUG

Furmonertinib

Drug: Furmonertinib

Trial Locations (1)

Unknown

RECRUITING

Changhai Hospital, Shanghai

All Listed Sponsors
collaborator

The General Hospital of Eastern Theater Command

OTHER

collaborator

Shanghai Chest Hospital

OTHER

collaborator

Fujian Provincial Hospital

OTHER

collaborator

Shanghai Changzheng Hospital

OTHER

collaborator

The First Affiliated Hospital of Bengbu Medical University

OTHER

collaborator

The First People's Hospital of Changzhou

OTHER

collaborator

Second Affiliated Hospital of Wannan Medical College

OTHER

lead

Changhai Hospital

OTHER